News Releases | Lucira Health, Inc

Year

22 Nov '22

Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care

PCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swab Positive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visit

17 Nov '22

Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service

Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costs Lucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 and

14 Nov '22

Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates

EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial

01 Nov '22

Lucira Health to Announce Third Quarter 2022 Financial Results

EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients

29 Sep '22

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays

Study Reveals Lucira’s Testing Assays Offer a 98% Accuracy Rate in Detecting Both Sexually Transmitted Infections EMERYVILLE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health” or “Lucira”), a medical technology company, today announced interim results of

07 Sep '22

Lucira Health to Participate in LifeSci Partners HealthTech Symposium

EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, and a digital health platform that will connect

23 Aug '22

Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

EMERYVILLE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in

15 Aug '22

Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates

EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial

11 Aug '22

Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test

EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today announced that Health

02 Aug '22

Lucira Health to Announce Second Quarter 2022 Financial Results

EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 28